Concepts (133)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Percutaneous Coronary Intervention | 10 | 2023 | 342 | 2.470 |
Why?
|
| Transcatheter Aortic Valve Replacement | 4 | 2022 | 314 | 1.770 |
Why?
|
| ST Elevation Myocardial Infarction | 4 | 2022 | 105 | 1.670 |
Why?
|
| Aortic Valve Stenosis | 4 | 2022 | 476 | 1.670 |
Why?
|
| Acute Coronary Syndrome | 5 | 2021 | 259 | 1.620 |
Why?
|
| Coronary Artery Bypass | 10 | 2023 | 708 | 1.060 |
Why?
|
| Non-ST Elevated Myocardial Infarction | 2 | 2021 | 16 | 0.940 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 2 | 2022 | 1021 | 0.850 |
Why?
|
| Aortic Valve | 4 | 2022 | 581 | 0.820 |
Why?
|
| Thrombolytic Therapy | 2 | 2021 | 257 | 0.810 |
Why?
|
| Sarcoma, Synovial | 1 | 2022 | 119 | 0.800 |
Why?
|
| Coronary Stenosis | 1 | 2022 | 117 | 0.760 |
Why?
|
| Myocardial Infarction | 4 | 2022 | 1374 | 0.680 |
Why?
|
| Coronary Artery Disease | 7 | 2023 | 1011 | 0.660 |
Why?
|
| Heart Valve Diseases | 1 | 2018 | 193 | 0.570 |
Why?
|
| Stroke | 3 | 2022 | 1144 | 0.560 |
Why?
|
| American Heart Association | 1 | 2018 | 310 | 0.550 |
Why?
|
| Betacoronavirus | 1 | 2020 | 527 | 0.510 |
Why?
|
| Renal Insufficiency, Chronic | 2 | 2022 | 787 | 0.510 |
Why?
|
| Atherosclerosis | 4 | 2023 | 935 | 0.490 |
Why?
|
| Heart Valve Prosthesis Implantation | 4 | 2022 | 563 | 0.480 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 651 | 0.420 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 715 | 0.420 |
Why?
|
| Electrocardiography | 2 | 2020 | 1145 | 0.400 |
Why?
|
| Mitral Valve Insufficiency | 2 | 2022 | 180 | 0.350 |
Why?
|
| Kidney Neoplasms | 1 | 2022 | 3022 | 0.330 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 2 | 2015 | 849 | 0.320 |
Why?
|
| Postoperative Complications | 5 | 2019 | 5542 | 0.290 |
Why?
|
| Treatment Outcome | 17 | 2023 | 32848 | 0.280 |
Why?
|
| Cardiovascular Diseases | 4 | 2023 | 2195 | 0.280 |
Why?
|
| Humans | 40 | 2023 | 261506 | 0.270 |
Why?
|
| Coronary Angiography | 2 | 2023 | 598 | 0.220 |
Why?
|
| Shock, Cardiogenic | 2 | 2022 | 228 | 0.210 |
Why?
|
| Hypothermia | 1 | 2021 | 59 | 0.200 |
Why?
|
| Purinergic P2Y Receptor Antagonists | 1 | 2021 | 48 | 0.200 |
Why?
|
| Endocarditis | 1 | 2022 | 125 | 0.190 |
Why?
|
| Platelet Aggregation Inhibitors | 2 | 2021 | 444 | 0.190 |
Why?
|
| Atherectomy, Coronary | 1 | 2020 | 16 | 0.190 |
Why?
|
| Out-of-Hospital Cardiac Arrest | 1 | 2021 | 89 | 0.180 |
Why?
|
| Hypothermia, Induced | 1 | 2021 | 170 | 0.180 |
Why?
|
| Angina Pectoris | 1 | 2020 | 80 | 0.180 |
Why?
|
| Comorbidity | 3 | 2022 | 2352 | 0.180 |
Why?
|
| Cardiomyopathy, Hypertrophic | 1 | 2022 | 192 | 0.180 |
Why?
|
| Heart Atria | 1 | 2022 | 352 | 0.180 |
Why?
|
| Inpatients | 2 | 2022 | 678 | 0.180 |
Why?
|
| Peripheral Arterial Disease | 1 | 2023 | 267 | 0.170 |
Why?
|
| Geriatric Assessment | 1 | 2020 | 275 | 0.160 |
Why?
|
| Aged | 11 | 2023 | 70117 | 0.160 |
Why?
|
| Hospitals | 1 | 2022 | 485 | 0.160 |
Why?
|
| Risk Factors | 8 | 2022 | 17523 | 0.160 |
Why?
|
| Cardiopulmonary Resuscitation | 1 | 2021 | 318 | 0.160 |
Why?
|
| Aspirin | 1 | 2021 | 455 | 0.150 |
Why?
|
| Ventricular Dysfunction, Left | 1 | 2020 | 435 | 0.140 |
Why?
|
| Cocaine | 1 | 2018 | 233 | 0.140 |
Why?
|
| Drug-Eluting Stents | 1 | 2017 | 131 | 0.140 |
Why?
|
| Preoperative Care | 2 | 2012 | 1529 | 0.140 |
Why?
|
| Adrenergic beta-Antagonists | 1 | 2018 | 323 | 0.140 |
Why?
|
| Psychiatric Rehabilitation | 1 | 2015 | 8 | 0.130 |
Why?
|
| Alcohol Abstinence | 1 | 2015 | 17 | 0.130 |
Why?
|
| Mitral Valve | 3 | 2022 | 271 | 0.130 |
Why?
|
| Pandemics | 2 | 2021 | 1559 | 0.120 |
Why?
|
| United States | 7 | 2023 | 15433 | 0.120 |
Why?
|
| Age Factors | 2 | 2020 | 5377 | 0.120 |
Why?
|
| Middle Aged | 10 | 2023 | 86204 | 0.110 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2023 | 1362 | 0.110 |
Why?
|
| Colchicine | 1 | 2012 | 52 | 0.110 |
Why?
|
| Diuretics | 1 | 2013 | 170 | 0.110 |
Why?
|
| Behavior Therapy | 1 | 2015 | 298 | 0.110 |
Why?
|
| Alcoholism | 1 | 2015 | 285 | 0.110 |
Why?
|
| Veterans | 1 | 2023 | 1641 | 0.100 |
Why?
|
| Pericarditis | 1 | 2012 | 61 | 0.100 |
Why?
|
| Aging | 1 | 2020 | 1582 | 0.100 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 1 | 2012 | 257 | 0.090 |
Why?
|
| Liver Diseases | 1 | 2015 | 574 | 0.090 |
Why?
|
| Cause of Death | 1 | 2013 | 752 | 0.090 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2021 | 2594 | 0.090 |
Why?
|
| Hospital Mortality | 3 | 2022 | 1274 | 0.090 |
Why?
|
| Heart Failure | 1 | 2023 | 2516 | 0.090 |
Why?
|
| Male | 11 | 2023 | 123000 | 0.080 |
Why?
|
| Surgical Wound Infection | 1 | 2012 | 450 | 0.080 |
Why?
|
| Female | 11 | 2023 | 141928 | 0.080 |
Why?
|
| Registries | 1 | 2015 | 2170 | 0.070 |
Why?
|
| Sepsis | 1 | 2012 | 652 | 0.070 |
Why?
|
| Risk Assessment | 1 | 2019 | 6869 | 0.070 |
Why?
|
| Pneumonia | 1 | 2012 | 751 | 0.070 |
Why?
|
| Diagnosis, Differential | 1 | 2012 | 4744 | 0.050 |
Why?
|
| Behavioral Risk Factor Surveillance System | 1 | 2022 | 60 | 0.050 |
Why?
|
| Coma | 1 | 2021 | 61 | 0.050 |
Why?
|
| Prasugrel Hydrochloride | 1 | 2021 | 25 | 0.050 |
Why?
|
| Myocardial Revascularization | 1 | 2022 | 134 | 0.050 |
Why?
|
| Atherectomy | 1 | 2020 | 12 | 0.050 |
Why?
|
| Mediastinum | 1 | 2022 | 268 | 0.050 |
Why?
|
| Observational Studies as Topic | 1 | 2020 | 140 | 0.050 |
Why?
|
| Prognosis | 1 | 2018 | 21713 | 0.040 |
Why?
|
| Cohort Studies | 1 | 2012 | 9244 | 0.040 |
Why?
|
| Mortality | 1 | 2022 | 343 | 0.040 |
Why?
|
| Health Status Disparities | 1 | 2023 | 291 | 0.040 |
Why?
|
| Vascular Calcification | 1 | 2020 | 50 | 0.040 |
Why?
|
| Bisoprolol | 1 | 2018 | 11 | 0.040 |
Why?
|
| Cholesterol | 1 | 2022 | 658 | 0.040 |
Why?
|
| Fibrinolytic Agents | 1 | 2021 | 324 | 0.040 |
Why?
|
| Atenolol | 1 | 2018 | 42 | 0.040 |
Why?
|
| Propanolamines | 1 | 2018 | 44 | 0.040 |
Why?
|
| Metoprolol | 1 | 2018 | 28 | 0.040 |
Why?
|
| Morbidity | 1 | 2019 | 397 | 0.040 |
Why?
|
| Retrospective Studies | 4 | 2013 | 37905 | 0.040 |
Why?
|
| Propranolol | 1 | 2018 | 156 | 0.040 |
Why?
|
| Blood Glucose | 1 | 2022 | 1244 | 0.040 |
Why?
|
| Patient Readmission | 1 | 2021 | 548 | 0.040 |
Why?
|
| Administration, Oral | 1 | 2021 | 1544 | 0.040 |
Why?
|
| Cardiac Catheterization | 1 | 2021 | 687 | 0.040 |
Why?
|
| Health Services Accessibility | 1 | 2022 | 761 | 0.030 |
Why?
|
| Survivors | 1 | 2021 | 1031 | 0.030 |
Why?
|
| Reoperation | 1 | 2020 | 1382 | 0.030 |
Why?
|
| Adult | 4 | 2023 | 77950 | 0.030 |
Why?
|
| Drug Therapy, Combination | 1 | 2021 | 2315 | 0.030 |
Why?
|
| Delivery of Health Care | 1 | 2022 | 860 | 0.030 |
Why?
|
| Global Health | 1 | 2019 | 657 | 0.030 |
Why?
|
| Follow-Up Studies | 3 | 2015 | 14889 | 0.030 |
Why?
|
| Survival Rate | 2 | 2019 | 12221 | 0.030 |
Why?
|
| Hospitalization | 1 | 2022 | 2083 | 0.030 |
Why?
|
| Cross-Sectional Studies | 1 | 2022 | 4314 | 0.030 |
Why?
|
| In Vitro Techniques | 1 | 2013 | 1618 | 0.020 |
Why?
|
| Postoperative Period | 1 | 2012 | 665 | 0.020 |
Why?
|
| Prospective Studies | 2 | 2015 | 12873 | 0.020 |
Why?
|
| Syndrome | 1 | 2012 | 1351 | 0.020 |
Why?
|
| Sex Factors | 1 | 2013 | 2139 | 0.020 |
Why?
|
| Odds Ratio | 1 | 2012 | 2316 | 0.020 |
Why?
|
| Logistic Models | 1 | 2013 | 3441 | 0.020 |
Why?
|
| Time Factors | 1 | 2017 | 12926 | 0.010 |
Why?
|
| Aged, 80 and over | 1 | 2023 | 29902 | 0.010 |
Why?
|
| Incidence | 1 | 2012 | 5673 | 0.010 |
Why?
|
| Texas | 1 | 2012 | 6311 | 0.010 |
Why?
|